Protagonist Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Protagonist TherapeuticsDie Umsatzerlöse und Gewinne des Unternehmens werden voraussichtlich um 5.3% bzw. 1.9% pro Jahr zurückgehen. Der Gewinn pro Aktie wird voraussichtlich zurückgehen um 3.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -19.9% betragen.

Wichtige Informationen

-23.9%

Wachstumsrate der Gewinne

-25.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	30.2%
Wachstumsrate der Einnahmen	-3.6%
Zukünftige Eigenkapitalrendite	-1.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	08 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21

Protagonist EPS beats by $0.03, beats on revenue

May 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:PTGX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	184	-24	23	172	5
12/31/2025	179	7	-141	-112	6
12/31/2024	285	119	193	274	6
6/30/2024	319	170	231	232	N/A
3/31/2024	315	162	-64	-63	N/A
12/31/2023	60	-79	-71	-70	N/A
9/30/2023	N/A	-140	-119	-119	N/A
6/30/2023	N/A	-138	-118	-117	N/A
3/31/2023	1	-140	-105	-105	N/A
12/31/2022	27	-127	-109	-108	N/A
9/30/2022	35	-130	-104	-103	N/A
6/30/2022	45	-133	-108	-107	N/A
3/31/2022	47	-122	-118	-117	N/A
12/31/2021	27	-126	-109	-108	N/A
9/30/2021	24	-108	-101	-100	N/A
6/30/2021	27	-81	-88	-88	N/A
3/31/2021	31	-70	-86	-85	N/A
12/31/2020	29	-66	-73	-72	N/A
9/30/2020	26	-65	-68	-68	N/A
6/30/2020	17	-73	-66	-66	N/A
3/31/2020	2	-83	-42	-41	N/A
12/31/2019	0	-77	-42	-42	N/A
9/30/2019	0	-74	-38	-37	N/A
6/30/2019	2	-66	-34	-32	N/A
3/31/2019	22	-45	-52	-51	N/A
12/31/2018	31	-39	-50	-50	N/A
9/30/2018	40	-28	-54	-54	N/A
6/30/2018	43	-24	-5	-4	N/A
3/31/2018	31	-31	N/A	-1	N/A
12/31/2017	20	-37	N/A	4	N/A
9/30/2017	9	-45	N/A	8	N/A
6/30/2017	N/A	-48	N/A	-39	N/A
3/31/2017	N/A	-40	N/A	-35	N/A
12/31/2016	N/A	-38	N/A	-30	N/A
9/30/2016	N/A	-32	N/A	-25	N/A
6/30/2016	N/A	-28	N/A	-22	N/A
3/31/2016	N/A	-24	N/A	-17	N/A
12/31/2015	N/A	-15	N/A	-14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PTGXFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.7% pro Jahr).

Ertrag vs. Markt: PTGXFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.7% pro Jahr).

Hohe Wachstumserträge: PTGXFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: PTGXDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-4.1% pro Jahr).

Hohe Wachstumseinnahmen: PTGXDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-4.1% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PTGX wird voraussichtlich in 3 Jahren unrentabel sein.

Protagonist Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Recent updates

Protagonist Therapeutics, Inc. Announces Publication of Phase 1 Clinical Data on JNJ-2113 in the Journal

Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024

Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control

Investor sentiment improves as stock rises 16%

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

CEO, President notifies of intention to sell stock

Executive VP & Chief Financial Officer recently sold US$378k worth of stock

Executive VP & Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

CEO, President notifies of intention to sell stock

Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Consensus revenue estimates increase by 102%

Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director

Chief Development Officer exercised options to buy US$282k worth of stock.

Consensus revenue estimates increase by 250%

New minor risk - Profitability

Consensus revenue estimates fall by 30%

Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director

Price target increased by 7.3% to US$39.00

Protagonist Therapeutics, Inc., Annual General Meeting, May 27, 2024

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Price target increased by 9.1% to US$37.83

Consensus revenue estimates increase by 100%

Protagonist Reports Positive Results from Phase 1 and Pre-Clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.43 loss in 1Q 2022)

Consensus revenue estimates fall by 51%

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Full year 2022 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor

Insider exercised options to buy US$812k worth of stock.

Insufficient new directors

Third quarter 2022 earnings released: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

Price target decreased to US$34.40

CEO, President exercised options to buy US$187k worth of stock.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Consensus revenue estimates increase by 28%

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Price target decreased to US$48.29

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$52.00

Insufficient new directors

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

CEO, President exercised options to buy US$680k worth of stock.

Protagonist Therapeutics, Inc., Annual General Meeting, May 26, 2022

Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Protagonist Is Still Being Undervalued Like There's Real Risk

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.21 loss in 3Q 2020)

CEO, President exercised options to buy US$720k worth of stock.